On July 18, the Government Accountability Office (GAO) issued a report that compares characteristics of hospitals participating in the 340 Drug Pricing Program with those not participating in the 340B Program. The report focuses on three types of hospitals that made up more than 95 percent of 340B participants in 2016.
The report examines the effects of Medicaid expansion on 340B participation and other characteristics such as rates of charity care provided.
Because for certain types of hospitals 340B eligibility is partially based on the number of Medicaid patients served, the report finds that 340B participation increased for those particular hospitals in states that expanded Medicaid.
Read the report summary.
View the full report.
Posted 07/25/18
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
